Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR-Reference-Cited by-同舟云学术

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

Published:2021-07-07 Issue:2 Volume:71 Page:461-471
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Kobayashi Takashi^ORCID,Ito Katsuhiro,Kojima Takahiro,Maruyama Satoru,Mukai Shoichiro,Tsutsumi Masakazu,Miki Jun,Okuno Tomoya,Yoshio Yuko,Matsumoto Hiroaki,Shimazui Toru,Segawa Takehiko,Karashima Takashi,Masui Kimihiko,Fukuta Fumimasa,Tashiro Kojiro,Imai Kazuto,Suekane Shigetaka,Nagasawa Seiji,Higashi Shin,Fukui Tomohiro,Ogawa Osamu,Kitamura Hiroshi,Nishiyama Hiroyuki

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-021-03000-8.pdf

Reference36 articles.

1. Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 376:1015–1026. https://doi.org/10.1056/NEJMoa1613683

2. Powles T, Park SH, Voog E et al (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 383:1218–1230. https://doi.org/10.1056/NEJMoa2002788

3. Galsky MD, Arija JAA, Bamias A et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547–1557. https://doi.org/10.1016/S0140-6736(20)30230-0

4. Powles T, van der Heijden MS, Castellano D et al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30541-6

5. Ogihara K, Kikuchi E, Shigeta K et al (2020) The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol Oncol 38(602):e1–e10. https://doi.org/10.1016/j.urolonc.2020.02.005

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era;World Journal of Urology;2024-05-09

2. Tumor–neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression;Proceedings of the National Academy of Sciences;2024-05-07

3. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;Nature Communications;2024-03-27

4. Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study;BMJ Open;2024-03

5. Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan;International Journal of Urology;2024-02